De Luca Leonardo, D'Errigo Paola, Rosato Stefano, Mureddu Gian Francesco, Badoni Gabriella, Seccareccia Fulvia, Baglio Giovanni
Department of Cardiosciences, A.O. San Camillo-Forlanini, Circonvallazione Gianicolense 87, 00152 Rome, Italy.
UniCamillus-Saint Camillus International, University of Health Sciences, Rome, Italy.
Eur Heart J Suppl. 2022 May 18;24(Suppl C):C225-C232. doi: 10.1093/eurheartj/suac013. eCollection 2022 May.
The long-term clinical benefits of myocardial revascularization in a contemporary, nationwide cohort of acute myocardial infarction (AMI) survivors are unclear. We aimed to compare the mortality rates and clinical outcomes at 8 years of patients admitted in Italy for a first AMI managed with or without myocardial revascularization during the index event. This is a national retrospective cohort study that enrolled patients admitted for a first AMI in 2012 in all Italian hospitals who survived at 30 days. The outcomes of interest were all-cause mortality, major cardio-cerebrovascular events (MACCE), and re-hospitalization for heart failure (HF) at 8 years. Time to events was analysed using a Cox and Fine and Gray multivariate regression model. A total of 127 431 patients with AMI were admitted to Italian hospitals in 2012. The study cohort consisted of 62 336 AMI events, of whom 63.8% underwent percutaneous or surgical revascularization ≤30 days of the index hospital admission. At 8 years, the cumulative incidence of all-cause death was 36.5% (24.6% in revascularized and 57.6% in not revascularized patients). After multiple corrections, the hazard ratio (HR) for all-cause mortality in revascularized vs. not revascularized patients was 0.61 ( < 0.0001). The rate of MACCE was 45.7% and 65.8% (adjusted HR 0.83; < 0.0001), while re-hospitalizations for HF occurred in 17.6% and 29.8% (adjusted HR 0.97; = 0.16) in AMI survivors revascularized and not revascularized, respectively. In our contemporary nationwide cohort of patients at their first AMI episode, those who underwent myocardial revascularization within 1 month from the index event compared to those not revascularized presented an adjusted 39% risk reduction in all-cause mortality and 17% in MACCE at 8-year follow-up.
在当代全国范围内的急性心肌梗死(AMI)幸存者队列中,心肌血运重建的长期临床益处尚不清楚。我们旨在比较在意大利因首次AMI入院的患者在8年时接受或未接受心肌血运重建治疗的死亡率和临床结局。这是一项全国性回顾性队列研究,纳入了2012年在意大利所有医院因首次AMI入院且存活30天的患者。感兴趣的结局是8年时的全因死亡率、主要心脑血管事件(MACCE)和因心力衰竭(HF)再次住院。使用Cox和Fine及Gray多变量回归模型分析事件发生时间。2012年共有127431例AMI患者入住意大利医院。研究队列包括62336例AMI事件,其中63.8%在指数医院入院后≤30天接受了经皮或外科血运重建。在8年时,全因死亡的累积发生率为36.5%(血运重建患者为24.6%,未血运重建患者为57.6%)。经过多次校正后,血运重建患者与未血运重建患者全因死亡率的风险比(HR)为0.61(<0.0001)。MACCE发生率分别为45.7%和65.8%(校正HR 0.83;<0.0001),而血运重建和未血运重建的AMI幸存者因HF再次住院的发生率分别为17.6%和29.8%(校正HR 0.97;=0.16)。在我们当代全国范围内首次发生AMI发作的患者队列中,与未进行血运重建的患者相比,在指数事件后1个月内接受心肌血运重建的患者在8年随访时全因死亡率调整风险降低39%,MACCE降低17%。